Decreased SARS-CoV-2 viral load following vaccination

Levine-Tiefenbrun, Matan; Yelin, Idan; Katz, Rachel; Herzel, Esma; Golan, Ziv; Schreiber, Licita; Wolf, Tamar; Nadler, Varda; Ben‐Tov, Amir; Kuint, Jacob; Gazit, Sivan; Patalon, Tal; Chodick, Gabriel; Kishony, Roy

doi:10.1101/2021.02.06.21251283

Cited by 70 publications

(54 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These vaccines express the spike glycoprotein, the major target of neutralising antibodies in a natural infection. The vaccines protect against disease,234 and preliminary data suggest that transmission is also decreased after vaccination 5…”

mentioning

confidence: 99%

Covid-19: variants and vaccination

Darby

Hiscox

2021

BMJ

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Covid-19: variants and vaccination

Darby

Hiscox

2021

BMJ

View full text Add to dashboard Cite

show abstract

“…Surprisingly, one dose efficacy against symptomatic disease was also very high 93-94% in trial data (2,4) with multiple sources of data around the world confirming a 80% to 90% one dose efficacy once sufficient time is given for the immune system to mount a response (5,6,7). Lower viral titres in those who had received one dose that do get infected would point to decreased transmission of virus even without the second dose (8) and asymptomatic infections also appear to be reduced by 4 fold (9). Our previous model showed that even high estimates of decay rates for one dose efficacy were highly unlikely to nullify the benefit to population immunity that was gained by deferring the second dose (10).…”

Section: Introductionmentioning

confidence: 99%

Modelled Optimization of SARS-Cov-2 Vaccine Distribution: an Evaluation of Second Dose Deferral Spacing of 6, 12, and 24 weeks

G¹,

Lackner²

2021

Preprint

View full text Add to dashboard Cite

Background: Multiple recent studies have shown strong first dose vaccine efficacy for both Moderna mRNA-1273 and Pfizer/BioNTech BNT 162b2, which has stimulated discussion of maximizing initial population immunity during a time of vaccine shortage by using a deferred second dose strategy for these vaccines. Methods: Our model examines the size of the effect of spacing of the second dose with 6, 12, and 24 week deferred spacing regimens relative to 3 week spacing. Results: Deferring the second dose from 3 weeks to 6 weeks, 12 weeks, and 24 weeks shows progressive benefit to population immunity for any given time period, even with significant one dose efficacy decay. The benefits are influenced by vaccine supply per capita. Conclusion: The longer the second dose is deferred the larger the benefit in initial population immunity, provided one dose efficacy does not significantly wane. Monitoring one dose efficacy duration from the UK or Quebec minimizes this risk, as the gathered data will help ensure the second dose is given at an optimal time. How this information is implemented should vary depending on the population and whether the goal is to optimally protect high risk groups or to increase total population immunity as quickly as possible. Benefits to deferring the second dose are influenced by the length of deferral, one dose efficacy, and vaccine supply per capita. The time to herd immunity could be shortened by 4 weeks with the implementation of a 12 week spacing regimen or 10 weeks with a 24 week spacing regimen.

show abstract

“…Recent findings suggest that vaccination against SARS-CoV2 prevents the transmission of COVID-19. [1] To achieve herd immunity and return to normality after months of restrictions, at least two-thirds of the population need to be vaccinated. [2] Wealthy countries have launched large-scale vaccination campaigns, with the UK leading the immunisation efforts in the European region.…”

Section: Introductionmentioning

confidence: 99%

Small donations making a huge difference: Individual contributions can facilitate worldwide vaccination against COVID-19

Sprengholz¹,

Korn²,

Eitze³

et al. 2021

Preprint

View full text Add to dashboard Cite

The COVAX initiative provides low- and middle-income countries with equitable access and financial support to source vaccines against COVID-19. The initiative is primarily funded by wealthy governments but should also consider promoting individual donations. We conducted a quota-representative study with 994 German participants to investigate individuals’ donation intentions. About one-third of participants expressed willingness to contribute to the initiative. When projecting these donations to the whole population, the initiative could raise hundreds of millions of euros in Germany alone. As people with stronger vaccination intentions are more willing to donate, vaccination centres could be an ideal setting for collecting donations.

show abstract

Decreased SARS-CoV-2 viral load following vaccination

Cited by 70 publications

References 11 publications

Covid-19: variants and vaccination

Covid-19: variants and vaccination

Modelled Optimization of SARS-Cov-2 Vaccine Distribution: an Evaluation of Second Dose Deferral Spacing of 6, 12, and 24 weeks

Small donations making a huge difference: Individual contributions can facilitate worldwide vaccination against COVID-19

Contact Info

Product

Resources

About